Venus Remedies jumepd 3.40% to Rs 321 after the company received good manufacturing practice (GMP) certification from Ministry of Health of Moldova for the company's antibiotic -Carbapenem facility.
The company said that it is well-positioned to further extend its presence in the eastern European market ensuring access to high quality, effective, and reliable antibiotics for healthcare providers and patients across the region.Venus Remedies is a global pharmaceutical company with a strong focus on fixed dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation.
The companys consolidated net profit declined 64.7% YoY to Rs 3.51 crore in Q2 FY25. Net sales fell marginally 0.2% to Rs 167.45 crore in Q2 FY25 as compared with Rs 167.72 crore in Q2 FY24.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
